ArticleCureus2025
Severe Dengue Associated With Hemophagocytic Lymphohistiocytosis (HLH) in an Adult ICU.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue virus infection is a growing global health concern, especially in tropical and subtropical regions. Dengue fever is commonly self-limiting, but sometimes, rare complications such as hemophagocytic lymphohistiocytosis (HLH) may occur, leading to fatal outcomes. HLH is a rare, hyperinflammatory syndrome marked by excessive immune activation, which can result in multiorgan failure and death. The relationship between dengue and HLH, particularly in adults, is not well understood, and early diagnosis and treatment remain critical for improving outcomes.
methodA total of 15 adult patients with severe dengue were admitted to a tertiary care ICU setting in North India from September to December 2023. Out of 15 patients, seven were diagnosed with dengue-associated HLH based on H-Score, and bone marrow aspiration was done in six patients. In this retrospective case series, we reviewed their clinical characteristics, laboratory findings, treatment regimens, and outcomes.
resultsThe median age of patients was 34 years, with female predominance. The Acute Physiology and Chronic Health Evaluation (APACHE) II score upon admission had a median value of 18, while the Sequential Organ Failure Assessment (SOFA) score at the time of HLH diagnosis had a median value of 11. The median day of illness at the time of HLH diagnosis was 23 days. The H-Score had a median value of 241 at the time of HLH diagnosis, supported by bone marrow aspiration, indicating a >99% probability of HLH. The mortality rate was 50%. Aggressive treatment with corticosteroid therapy, intravenous immunoglobulin (IVIG), or a combination of both, along with other supportive care, was given to the patients.
conclusionPersistent fever, altered mental status, bicytopenia, elevated triglyceride levels, and markedly elevated serum ferritin levels are important to differentiate dengue-associated HLH from severe dengue. H-Score can assist in the early identification of HLH. Early recognition and timely initiation of HLH-targeted therapy are essential for improving survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.